Page 2 - Factor Bioscience News Today

Author Bio George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies. Follow @BudwellGeorge What happened Brooklyn ImmunoTherapeutics (NYSEMKT:BTX), a relative newcomer to the world of publicly traded biotech stocks, saw its shares rip higher in April by a stunning 1,230%, according to data provided by S&P Globa...

Why Brooklyn ImmunoTherapeutics Is Surging Higher Again Today Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) is moving higher again on Monday morning as the stock continues to increase in popularity on the subreddit r/wallstreetbets. What Happened: The stock has soared over the last week after Reddit traders identified the stock as a low float high short interest short squeeze candidate. Last Thursday, the company announced it had acquired an exclusive license for mRNA gene editing and cell ...

Share: Brooklyn Immuno Therapeutics Inc. (NYSE: BTX) shares are soaring Friday. The stock is likely continuing its run after the company paid $1 million towards the acquisition of a license for Factor Bioscience’s and Novellus mRNA gene editing and cell therapies technology. If the license agreement is completed, it allows Brooklyn Therapeutics to utilize a patented process to seek to develop gene-edited compounds using mRNA. Below is a chart analysis on the 15-minute timeframe. Brooklyn The...

Posted on 3044 Brooklyn ImmoTherapeutics LLC (NYSE: BTX)reported that is has acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited.  This will include an extensive patented process to develop gene editing compounds by utilizing mRNA which preclinical data has demonstrated a high level of efficiency.  mRNA cell reprogramming is considered the ...

Novavax, Inc Novavax, Inc. is a clinical-stage vaccine company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. With the onset of the global pandemic last year, the company has also ventured into making COVID-19 vaccines. Despite not having any product in the market yet and facing delays in production, it is still expected to be one of the leading vaccine candidates. The company’s vaccine has proven to be just as potent as o...

NUIG researchers developing new cell therapy for severe Covid-19 16 March 2021 print Galway Bay fm newsroom – Researchers at NUI Galway have entered into a international research partnership to develop a new cell therapy for those with severe Covid-19 infection. The partnership, between CÚRAM at NUIG and US-based Factor Bioscience, will also look to treat those with other serious respiratory illnesses. Most people who die of Covid-19 die of acute respiratory distress syndrome, or ARDS. This ...

Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer - Names key executive Dirk Huebner MD, as Chief Medical Officer - Immuno-oncology cell therapy company creates innovative, stealth and performance engineered T and NK cells from induced pluripotent stem cells (iPSCs) - Uses proprietary mRNA-based cell engineering to develop cancer cell therapies - avoids viruses and DNA News provided by Share this article Share th...

Share this article Share this article CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced its formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company. The exclusive license allows Exacis to create allogeneic engineered T and NK cells from induced pluripotent stem cells (iPSC). Exacis ...